COVID-19 is an infectious disease caused by the SARS COV-2 virus. Patients with COVID-19 are susceptible to thrombosis due to excessive inflammation, platelet activation, endothelial dysfunction, and circulatory stasis, resulting in an increased risk of death due to associated coagulopathies. In addition, many patients receiving antithrombotic therapy for pre-existing thrombotic diseases can develop COVID-19, which can further complicate dose adjustment, choice and laboratory monitoring of antithrombotic treatment. This review summarizes the laboratory findings, the prohemostatic state, incidence of thromboembolic events and some potential therapeutic interventions of COVID-19 associated coagulopathy. We explore the roles of biomarkers of thrombosis and inflammation according to the severity of COVID-19. While therapeutic anticoagulation has been used empirically in some patients with severe COVID-19 but without thrombosis, it may be preferable to provide supportive care based on evidence-based randomized clinical trials. The likely lifting of travel restrictions will accelerate the spread of COVID-19, increasing morbidity and mortality across nations. Many individuals will continue to receive anticoagulation therapy regardless of their location, requiring on-going treatment with low-molecular weight heparin, vitamin K antagonist or direct-acting anticoagulants.
【저자키워드】 COVID-19, SARS-CoV-2, thrombosis, Disseminated intravascular coagulation, antithrombotic therapy, Anticoagulant, antiplatelet, 【초록키워드】 Treatment, Inflammation, platelet activation, therapy, Biomarker, anticoagulation, severe COVID-19, Infectious disease, virus, Endothelial dysfunction, Laboratory, Coagulopathy, severity of COVID-19, Patient, Travel, death, morbidity and mortality, incidence, randomized clinical trials, Coagulopathies, disease, therapeutic anticoagulation, Anticoagulants, supportive care, Antithrombotic, dose, increased risk, individual, thrombotic, therapeutic intervention, excessive inflammation, while, direct-acting, Thromboembolic event, susceptible, spread of COVID-19, resulting, develop, caused, addition, receiving, accelerate, receive, complicate, with COVID-19, 【제목키워드】 tendency, disproportionate,